Literature DB >> 742875

Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole.

J P Sosna, P R Murray, G Medoff.   

Abstract

The in vitro activity of HR756, a new semisynthetic cephalosporin, was compared with the activities of cephalothin, cefoxitin, and cefamandole against 1,535 isolates of gram-positive and gram-negative bacteria. HR756 was less active than cephalothin and cefamandole and twofold more active than cefoxitin against Staphylococcus. All four of the antibiotics were inactive against the enterococcus group of Streptococcus; however, HR756 was the most active antibiotic against the other isolates of Streptococcus. HR756 was also more active against isolates of Enterobacteriaceae, including 84 to 95% of the isolates resistant to one or more of the other three antibiotics. HR756, at a concentration of 12.5 mug/ml, inhibited 86, 75, and 100% of the isolates of Pseudomonas aeruginosa, other Pseudomonas species, and Acinetobacter, respectively. The minimal inhibitory concentrations and minimal bactericidal concentrations of HR756 were within one twofold dilution for 11 of 21 gram-positive cocci and 119 of 125 gram-negative bacilli tested.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 742875      PMCID: PMC352572          DOI: 10.1128/AAC.14.6.876

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  Drug therapy: The newer cephalosporins.

Authors:  R C Moellering; M N Swartz
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

2.  Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin.

Authors:  C G Mayhall; G Medoff; J J Marr
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

Review 3.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

4.  The in vitro spectrum of the cephalosporins.

Authors:  J A Washington
Journal:  Mayo Clin Proc       Date:  1976-04       Impact factor: 7.616

5.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

  5 in total
  33 in total

1.  In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae.

Authors:  P R Murray; J L Christman; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

2.  An overview of cefotaxime therapy in infections caused by gram-positive pathogens.

Authors:  P B Iannini
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.

Authors:  R P Mouton; G P Bongaerts; M van Gestel
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  Ceftazidime, ceftizoxime, cefotaxime and HR 221 in experimental chronic Escherichia coli pyelonephritis in rats.

Authors:  R Marre; D Herhahn; E Schulz; H Freiesleben; K Sack
Journal:  Infection       Date:  1983       Impact factor: 3.553

6.  In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzae.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.

Authors:  P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  In vitro antimicrobial activity of cefotaxime, a new cephalosporin.

Authors:  S Masuyoshi; S Arai; M Miyamoto; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

10.  Cephalosporins: recent developments.

Authors:  A Kumar
Journal:  J Natl Med Assoc       Date:  1983-02       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.